These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35902413)

  • 1. Pediatric Heart Network Trial of Losartan vs. Atenolol in Children and Young Adults with Marfan Syndrome: Impact on Prescription Practices.
    Robertson DM; Truong DT; Cox DA; Carmichael HL; Ou Z; Minich LL; Williams RV; Selamet Tierney ES
    Pediatr Cardiol; 2023 Mar; 44(3):618-623. PubMed ID: 35902413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.
    Brooke BS; Habashi JP; Judge DP; Patel N; Loeys B; Dietz HC
    N Engl J Med; 2008 Jun; 358(26):2787-95. PubMed ID: 18579813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
    Chiu HH; Wu MH; Wang JK; Lu CW; Chiu SN; Chen CA; Lin MT; Hu FC
    Mayo Clin Proc; 2013 Mar; 88(3):271-6. PubMed ID: 23321647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis.
    Kang YN; Chi SC; Wu MH; Chiu HH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):182-190. PubMed ID: 31003918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
    Teixido-Tura G; Forteza A; Rodríguez-Palomares J; González Mirelis J; Gutiérrez L; Sánchez V; Ibáñez B; García-Dorado D; Evangelista A
    J Am Coll Cardiol; 2018 Oct; 72(14):1613-1618. PubMed ID: 30261963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.
    Lacro RV; Guey LT; Dietz HC; Pearson GD; Yetman AT; Gelb BD; Loeys BL; Benson DW; Bradley TJ; De Backer J; Forbus GA; Klein GL; Lai WW; Levine JC; Lewin MB; Markham LW; Paridon SM; Pierpont ME; Radojewski E; Selamet Tierney ES; Sharkey AM; Wechsler SB; Mahony L;
    Am Heart J; 2013 May; 165(5):828-835.e3. PubMed ID: 23622922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.
    Pitcher A; Spata E; Emberson J; Davies K; Halls H; Holland L; Wilson K; Reith C; Child AH; Clayton T; Dodd M; Flather M; Jin XY; Sandor G; Groenink M; Mulder B; De Backer J; Evangelista A; Forteza A; Teixido-Turà G; Boileau C; Jondeau G; Milleron O; Lacro RV; Sleeper LA; Chiu HH; Wu MH; Neubauer S; Watkins H; Dietz H; Baigent C;
    Lancet; 2022 Sep; 400(10355):822-831. PubMed ID: 36049495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atenolol versus losartan in children and young adults with Marfan's syndrome.
    Lacro RV; Dietz HC; Sleeper LA; Yetman AT; Bradley TJ; Colan SD; Pearson GD; Selamet Tierney ES; Levine JC; Atz AM; Benson DW; Braverman AC; Chen S; De Backer J; Gelb BD; Grossfeld PD; Klein GL; Lai WW; Liou A; Loeys BL; Markham LW; Olson AK; Paridon SM; Pemberton VL; Pierpont ME; Pyeritz RE; Radojewski E; Roman MJ; Sharkey AM; Stylianou MP; Wechsler SB; Young LT; Mahony L;
    N Engl J Med; 2014 Nov; 371(22):2061-71. PubMed ID: 25405392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.
    Lacro RV; Dietz HC; Wruck LM; Bradley TJ; Colan SD; Devereux RB; Klein GL; Li JS; Minich LL; Paridon SM; Pearson GD; Printz BF; Pyeritz RE; Radojewski E; Roman MJ; Saul JP; Stylianou MP; Mahony L;
    Am Heart J; 2007 Oct; 154(4):624-31. PubMed ID: 17892982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
    Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.
    Van Driest SL; Sleeper LA; Gelb BD; Morris SA; Dietz HC; Forbus GA; Goldmuntz E; Hoskoppal A; James J; Lee TM; Levine JC; Li JS; Loeys BL; Markham LW; Meester JAN; Mital S; Mosley JD; Olson AK; Renard M; Shaffer CM; Sharkey A; Young L; Lacro RV; Roden DM
    J Pediatr; 2020 Jul; 222():213-220.e5. PubMed ID: 32586526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
    Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
    Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluting Stents.
    Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):55-67. PubMed ID: 30632033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome.
    Mueller GC; Stierle L; Stark V; Steiner K; von Kodolitsch Y; Weil J; Mir TS
    Heart; 2014 Feb; 100(3):214-8. PubMed ID: 24270746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic effect of angiotensin receptor blockers in children with genetic aortopathies: the early bird catches the worm.
    Olfe J; Kanitz JJ; Stark VC; Stute F; von Kodolitsch Y; Biermann D; Huebler M; Kozlik-Feldmann R; Mir TS
    Clin Res Cardiol; 2023 Nov; 112(11):1610-1619. PubMed ID: 37160466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin Receptor Blockers vs. Beta-Blocker Therapy for Marfan Syndrome: A Systematic Review and Meta-Analysis.
    Wang Z; Deng X; Kang X; Hu A
    Ann Vasc Surg; 2022 May; 82():347-361. PubMed ID: 34998935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis Examining the Usefulness of Angiotensin Receptor blockers for the Prevention of Aortic Root Dilation in Patients With the Marfan Syndrome.
    Al-Abcha A; Saleh Y; Mujer M; Boumegouas M; Herzallah K; Charles L; Elkhatib L; Abdelkarim O; Kehdi M; Abela GS
    Am J Cardiol; 2020 Aug; 128():101-106. PubMed ID: 32650901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome.
    Thakur V; Rankin KN; Hartling L; Mackie AS
    Cardiol Young; 2013 Aug; 23(4):568-81. PubMed ID: 23083542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications.
    Singh MN; Lacro RV
    Can J Cardiol; 2016 Jan; 32(1):66-77. PubMed ID: 26724512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes.
    Sandor GG; Alghamdi MH; Raffin LA; Potts MT; Williams LD; Potts JE; Kiess M; van Breemen C
    Int J Cardiol; 2015 Jan; 179():470-5. PubMed ID: 25465809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.